Meanwhile, the effect of MTHFD1 knockdown or anti-folic acid metabolism drug methotrexate (MTX) combined with the BRD4 inhibitor JQ1 was also evaluated, aiming to identify the potential of MTHFD1 as a therapy target for NB, and to reveal the importance of targeted inhibition of folic acid metabolism pathway for NB therapy. Here, BRD4 is linked to neuroblastoma.